UCB SA (OTCMKTS:UCBJF) Given Average Recommendation of “Moderate Buy” by Analysts

UCB SA (OTCMKTS:UCBJF) has received an average rating of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company.

Separately, Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a report on Wednesday.

UCB Price Performance

OTCMKTS:UCBJF opened at $290.59 on Wednesday. UCB has a fifty-two week low of $207.00 and a fifty-two week high of $345.39. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The firm has a 50-day simple moving average of $292.35 and a two-hundred day simple moving average of $300.88.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.